BlackRock Fund Advisors recently announced the acquisition of new stake in Athira Pharma Inc. (NASDAQ:ATHA). The institutional investor has increased its shareholding in the Healthcare company by 5.09% to 2.37 million shares with purchase of 0.11 million shares. This fresh investment now brings its stake to 6.26% valued currently at $7.5 million. In addition, Pathstone Family Office LLC raised its holdings by 0.13 million to 1.82 million shares. And The Vanguard Group, Inc. has lifted its position by 14.02% or 0.22 million shares – to 1.8 million shares.
With over 0.34 million Athira Pharma Inc. (ATHA) shares trading Friday and a closing price of $3.85 on the day, the dollar volume was approximately $1.32 million. The shares have shown a positive half year performance of 11.92% and its price on 01/13/23 gained nearly 1.85%. Currently, there are 37.82M common shares owned by the public and among those 35.89M shares have been available to trade.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 6 analysts who have offered their price forecasts for ATHA have a consensus price objective of $11.75. The analysts have set the share’s price value over the next 12 months at a high of $33.00 and a low of $3.00. The average price target is 67.23% above its recent price level and a downside to the estimated low will see the stock lose -28.33% over that period. But an upside of 88.33% will see the stock hit the forecast high price target while median target price for the stock is $5.50.
Insiders at the company have transacted a total of 27 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 22 of these insider trades were purchases, accounting for 1,522,411 shares. Insider sales of the common stock occurred on 5 occasions, with total insider shares sold totaling 19,995 shares.
The top 3 mutual fund holders in Athira Pharma Inc. are Vanguard Total Stock Market Index, iShares Russell 2000 ETF, and Vanguard Extended Market Index Fu. Vanguard Total Stock Market Index owns 1.18 million shares of the company’s stock, all valued at over $3.75 million. iShares Russell 2000 ETF sold 9089.0 shares to see its total holdings shrink to 0.87 million shares valued at over $2.76 million and representing 2.30% of the shares outstanding. Vanguard Extended Market Index Fu now owns shares totaling to 1.21% of the shares outstanding.
However, the script later moved the day high at 4.0000, up 1.85%. The company’s stock has a 5-day price change of 11.59% and 18.10% over the past three months. ATHA shares are trading 21.45% year to date (YTD), with the 12-month market performance down to -67.46% lower. It has a 12-month low price of $2.53 and touched a high of $14.22 over the same period. ATHA has an average intraday trading volume of 283.07K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 17.88%, 22.13%, and -27.07% respectively.
Institutional ownership of Athira Pharma Inc. (NASDAQ: ATHA) shares accounts for 64.50% of the company’s 37.82M shares outstanding. Mutual fund holders own 14.41%, while other institutional holders and individual stakeholders account for 45.51% and 13.40% respectively.
It has a market capitalization of $142.99M. The earnings-per-share (ttm) stands at -$2.10. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.91% over the week and 6.17% over the month.
Analysts forecast that Athira Pharma Inc. (ATHA) will achieve an EPS of -$0.63 for the current quarter, -$0.67 for the next quarter and -$2.77 for 2023. The lowest estimate earnings-per-share for the quarter is -$0.69 while analysts give the company a high EPS estimate of -$0.57. Comparatively, EPS for the current quarter was -$0.42 a year ago. Earnings per share for the fiscal year are expected to decrease by -141.90%, and -22.20% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 6 brokerage firm advisors rate Athira Pharma Inc. (ATHA) as a “Moderate Buy” at a consensus score of 2.30. Specifically, 3 Wall Street analysts polled rate the stock as a buy, while 3 of the 6 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the ATHA, a number of firms have released research notes about the stock. JMP Securities stated their Mkt Outperform rating for the stock in a research note on October 17, 2022, with the firm’s price target at $20. Mizuho coverage for the Athira Pharma Inc. (ATHA) stock in a research note released on July 07, 2022 offered a Buy rating with a price target of $6. Jefferies on their part issued Hold rating on June 23, 2022.
